


ETCTN Trials by Disease/ Treatment Area: Head and Neck/Thyroid Cancer



NOTE: \* No ClinicalTrials.gov webpage is available currently (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide

ETCTN Head/Neck and Thyroid Cancer Trials (Open as of 3/10/2026)

<b>Protocol Number</b>	<b>Phase</b>	<b>Protocol Title</b>
<b>10492</b>	I/Ib	Phase I/Ib Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer
<b>10553</b>	II	A Phase II Clinical and Biomarker Study of Darolutamide in Combination with Androgen Deprivation Therapy (ADT) for Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer Patients
<b>10706</b>	I/II	A Phase 2 Window of Opportunity Trial of Neoadjuvant Agonistic Anti-CD40 Antibody CDX-1140 and Cemiplimab in AJCC Stage III-IV Head and Neck Cancer Patients Prior to Surgery
<b>10721</b>	II	Neoadjuvant Chemotherapy with or without Cemiplimab (REGN2810) in Sinonasal Squamous Cell Carcinoma: A Randomized Phase 2 Study
<b>10732</b>	I	Phase I Trial of ATR Inhibitor Camonsertib Combined with Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma